Adolfo A. Ferrando

Adolfo A. Ferrando's AcademicInfluence.com Rankings

Adolfo A. Ferrando

Philosophy

#9072

World Rank

#12573

Historical Rank

Logic

#6068

World Rank

#7549

Historical Rank

philosophy Degrees

Download Badge

Philosophy

Adolfo A. Ferrando's Degrees

Masters Medicine University of Buenos Aires
PhD Biomedical Sciences University of Buenos Aires

Why Is Adolfo A. Ferrando Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Adolfo A. Ferrando's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

MicroRNA expression profiles classify human cancers (2005) (9561)
Activating Mutations of NOTCH1 in Human T Cell Acute Lymphoblastic Leukemia (2004) (2737)
Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. (2012) (1728)
Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. (2002) (1105)
Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia (2007) (880)
NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth (2006) (840)
Non-coding recurrent mutations in chronic lymphocytic leukaemia (2015) (654)
Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity (2007) (535)
Myc-Induced T Cell Leukemia in Transgenic Zebrafish (2003) (524)
The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia (2007) (474)
Recurrent mutations in epigenetic regulators, RHOA and FYN kinase in peripheral T cell lymphomas (2014) (467)
The molecular basis of T cell acute lymphoblastic leukemia. (2012) (440)
Fusion of NUP214 to ABL1 on amplified episomes in T-cell acute lymphoblastic leukemia (2004) (432)
In vivo tracking of T cell development, ablation, and engraftment in transgenic zebrafish. (2004) (383)
γ-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia (2009) (373)
Oncogenic IL7R gain-of-function mutations in childhood T-cell acute lymphoblastic leukemia (2011) (370)
Requirement for cyclin D3 in lymphocyte development and T cell leukemias. (2003) (362)
Gene expression signatures in MLL-rearranged T-lineage and B-precursor acute leukemias: dominance of HOX dysregulation. (2003) (350)
Integrated transcript and genome analyses reveal NKX2-1 and MEF2C as potential oncogenes in T cell acute lymphoblastic leukemia. (2011) (328)
T-cell acute lymphoblastic leukemia in adults: clinical features, immunophenotype, cytogenetics, and outcome from the large randomized prospective trial (UKALL XII/ECOG 2993). (2009) (327)
Genome-wide RNA-mediated interference screen identifies miR-19 targets in Notch-induced T-cell acute lymphoblastic leukaemia (2010) (322)
Contrasting roles for histone 3 lysine 27 demethylases in acute lymphoblastic leukemia (2014) (311)
The genetics and mechanisms of T cell acute lymphoblastic leukaemia (2016) (302)
The mutational landscape of cutaneous T cell lymphoma and Sézary syndrome (2015) (300)
Activating mutations in the NT5C2 nucleotidase gene drive chemotherapy resistance in relapsed ALL (2013) (296)
Targeting the NF-κB signaling pathway in Notch1-induced T-cell leukemia (2007) (287)
The Ubiquitin Ligase FBXW7 Modulates Leukemia-Initiating Cell Activity by Regulating MYC Stability (2013) (285)
PHF6 mutations in T-cell acute lymphoblastic leukemia (2010) (264)
The role of the PTEN/AKT Pathway in NOTCH1-induced leukemia (2008) (236)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity (2019) (232)
DNA hydroxymethylation profiling reveals that WT1 mutations result in loss of TET2 function in acute myeloid leukemia. (2014) (231)
A NOTCH1-driven MYC enhancer promotes T cell development, transformation and acute lymphoblastic leukemia (2014) (230)
Direct reversal of glucocorticoid resistance by AKT inhibition in acute lymphoblastic leukemia. (2013) (218)
Genetic Inactivation of the PRC2 Complex in T-Cell Acute Lymphoblastic Leukemia (2011) (214)
CXCL12-Producing Vascular Endothelial Niches Control Acute T Cell Leukemia Maintenance. (2015) (211)
Human MT6-matrix metalloproteinase: identification, progelatinase A activation, and expression in brain tumors. (2000) (198)
The role of NOTCH1 signaling in T-ALL. (2009) (191)
Targeting the NF-kappaB signaling pathway in Notch1-induced T-cell leukemia. (2007) (187)
ETV6 mutations in early immature human T cell leukemias (2011) (186)
Multivalent Small-Molecule Pan-RAS Inhibitors (2017) (186)
Structure and expression in breast tumors of human TIMP-3, a new member of the metalloproteinase inhibitor family. (1994) (179)
Slug, a highly conserved zinc finger transcriptional repressor, protects hematopoietic progenitor cells from radiation-induced apoptosis in vivo. (2002) (179)
Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia (2010) (178)
Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia (2009) (170)
Prognostic importance of TLX1 (HOX11) oncogene expression in adults with T-cell acute lymphoblastic leukaemia (2004) (165)
Search for narrow resonances using the dijet mass spectrum in pp collisions at √s=8 TeV (2013) (160)
CSL–MAML-dependent Notch1 signaling controls T lineage–specific IL-7Rα gene expression in early human thymopoiesis and leukemia (2009) (155)
CUTLL1, a novel human T-cell lymphoma cell line with t(7;9) rearrangement, aberrant NOTCH1 activation and high sensitivity to γ-secretase inhibitors (2006) (155)
Mutational landscape, clonal evolution patterns, and role of RAS mutations in relapsed acute lymphoblastic leukemia (2016) (154)
Reverse engineering of TLX oncogenic transcriptional networks identifies RUNX1 as tumor suppressor in T-ALL (2011) (153)
The TLX1 oncogene drives aneuploidy in T-cell transformation (2010) (153)
Clinical implications of recurring chromosomal and associated molecular abnormalities in acute lymphoblastic leukemia. (2000) (150)
The NOTCH1-MYC highway toward T-cell acute lymphoblastic leukemia. (2017) (148)
PHF6 mutations in adult acute myeloid leukemia (2011) (147)
The BCL2A1 gene as a pre–T cell receptor–induced regulator of thymocyte survival (2005) (141)
Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. (2011) (140)
Biallelic transcriptional activation of oncogenic transcription factors in T-cell acute lymphoblastic leukemia. (2004) (139)
Gene expression profiling in T-cell acute lymphoblastic leukemia. (2003) (138)
How I treat T-cell acute lymphoblastic leukemia in adults. (2015) (137)
Prognostic relevance of integrated genetic profiling in adult T-cell acute lymphoblastic leukemia. (2012) (131)
NOTCH1 extracellular juxtamembrane expansion mutations in T-ALL. (2008) (129)
RHOA G17V Induces T Follicular Helper Cell Specification and Promotes Lymphomagenesis. (2018) (128)
NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia (2009) (128)
WT1 mutations in T-ALL. (2009) (127)
Negative feedback–defective PRPS1 mutants drive thiopurine resistance in relapsed childhood ALL (2015) (126)
HES1 opposes a PTEN-dependent check on survival, differentiation, and proliferation of TCRβ-selected mouse thymocytes. (2012) (123)
Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in acute lymphoblastic leukemia (2015) (116)
Activating FLT3 mutations in CD117/KIT(+) T-cell acute lymphoblastic leukemias. (2004) (115)
Regulation of T‐cell progenitor survival and cell‐cycle entry by the pre‐T‐cell receptor (2006) (112)
Therapeutic effect of γ-secretase inhibition in KrasG12V-driven non-small cell lung carcinoma by derepression of DUSP1 and inhibition of ERK. (2012) (108)
Genetic loss of SH2B3 in acute lymphoblastic leukemia. (2013) (107)
Prognostic implications of NOTCH1 and FBXW7 mutations in adults with T-cell acute lymphoblastic leukemia treated on the MRC UKALLXII/ECOG E2993 protocol. (2009) (103)
Common nonmutational NOTCH1 activation in chronic lymphocytic leukemia (2017) (100)
Human cathepsin O. Molecular cloning from a breast carcinoma, production of the active enzyme in Escherichia coli, and expression analysis in human tissues. (1994) (99)
Targeting nonclassical oncogenes for therapy in T-ALL. (2012) (94)
N-Me, a long range oncogenic enhancer in T-cell acute lymphoblastic leukemia (2014) (91)
Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. (2010) (91)
Metabolic reprogramming induces resistance to anti-NOTCH1 therapies in T cell acute lymphoblastic leukemia (2015) (89)
ChIP-on-chip significance analysis reveals large-scale binding and regulation by human transcription factor oncogenes (2007) (86)
Preclinical Analysis of the γ-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia (2012) (86)
Clonal evolution mechanisms in NT5C2 mutant relapsed acute lymphoblastic leukemia (2017) (84)
Clonal evolution in leukemia (2017) (83)
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T-cell lymphomas (2017) (83)
The NOTCH signaling pathway: role in the pathogenesis of T-cell acute lymphoblastic leukemia and implication for therapy (2013) (82)
Decreased expression of peroxisome proliferator activated receptor γ in CFTR−/− mice (2004) (78)
Oncogenic NOTCH1 Control of MYC and PI3K: Challenges and Opportunities for Anti-NOTCH1 Therapy in T-Cell Acute Lymphoblastic Leukemias and Lymphomas (2008) (76)
Pharmacological inhibition of the transcription factor PU.1 in leukemia (2017) (76)
Early T-cell precursor acute lymphoblastic leukaemia (2013) (75)
Gamma-secretase inhibitors reverse glucocorticoid resistance in T-ALL (2008) (74)
Transcriptional regulatory networks downstream of TAL1/SCL in T-cell acute lymphoblastic leukemia. (2005) (74)
Hematopoietic Stem Cell Differentiation Regulated by a Single Ubiquitin Ligase: Substrate Complex (2009) (68)
Activating mutations in NOTCH1 in acute myeloid leukemia and lineage switch leukemias (2006) (68)
Towards patient-based cancer therapeutics (2010) (65)
Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. (2009) (65)
Various types of rearrangements target TLX3 locus in T‐cell acute lymphoblastic leukemia (2004) (63)
A conserved tetraspanin subfamily promotes Notch signaling in Caenorhabditis elegans and in human cells (2010) (62)
Cloning and expression analysis of human bleomycin hydrolase, a cysteine proteinase involved in chemotherapy resistance. (1996) (61)
Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia (2018) (61)
Recent advances on NOTCH signaling in T-ALL. (2012) (58)
A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia (2006) (56)
Patient-derived xenotransplants can recapitulate the genetic driver landscape of acute leukemias (2016) (52)
Metabolic dependencies and vulnerabilities in leukemia (2019) (51)
IL-7-dependent human leukemia T-cell line as a valuable tool for drug discovery in T-ALL. (2004) (49)
Synergistic antileukemic therapies in NOTCH1-induced T-ALL (2017) (44)
Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas (2004) (42)
Phf6 Loss Enhances HSC Self-Renewal Driving Tumor Initiation and Leukemia Stem Cell Activity in T-ALL. (2018) (40)
Redundancy and specificity of the metalloprotease system mediating oncogenic NOTCH1 activation in T-ALL (2011) (38)
Therapeutic targeting of HES1 transcriptional programs in T-ALL. (2015) (37)
Covalent inhibition of NSD1 histone methyltransferase (2020) (37)
The zebrafish reveals dependence of the mast cell lineage on Notch signaling in vivo. (2012) (36)
NOTCH mutations as prognostic markers in T-ALL (2010) (34)
Erratum: NOTCH1 directly regulates c-MYC and activates a feed-forward-loop transcriptional network promoting leukemic cell growth (Proceedings of the National Academy of Sciences of the United States of America (2006) 103, 48, (18261-18266) DOI: 10.1073/pnas.0606108103) (2007) (32)
MMP-25 Metalloprotease Regulates Innate Immune Response through NF-κB Signaling (2016) (31)
Structure and Mechanisms of NT5C2 Mutations Driving Thiopurine Resistance in Relapsed Lymphoblastic Leukemia. (2018) (30)
Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias. (2015) (30)
Enhancer hijacking drives oncogenic BCL11B expression in lineage ambiguous stem cell leukemia. (2021) (29)
Genetics and mechanisms of NT5C2-driven chemotherapy resistance in relapsed ALL. (2019) (29)
Leukemia-specific delivery of mutant NOTCH1 targeted therapy (2016) (27)
Pediatric T- and NK-cell lymphomas: new biologic insights and treatment strategies (2012) (25)
Can one target T-cell ALL? (2018) (24)
The subclonal complexity of STIL-TAL1+ T-cell acute lymphoblastic leukaemia (2018) (23)
Activating Notch1 mutations are an early event in T-cell malignancy of Ikaros point mutant Plastic/+ mice. (2007) (23)
Mutational and functional genetics mapping of chemotherapy resistance mechanisms in relapsed acute lymphoblastic leukemia (2020) (22)
Gata3-controlled nucleosome eviction drives Myc enhancer activity in T-cell development and leukemia. (2019) (22)
Prostate-specific membrane antigen in breast carcinoma (1997) (22)
An activating intragenic deletion in NOTCH1 in human T-ALL. (2012) (21)
The role of NOTCH 1 signaling in TALL (2009) (20)
DNA Microarrays in the Diagnosis and Management of Acute Lymphoblastic Leukemia (2004) (19)
Disregulated expression of the transcription factor ThPOK during T-cell development leads to high incidence of T-cell lymphomas (2015) (18)
Gain-of-Function NOTCH1 Mutations Occur Frequently in Human T Cell Acute Lymphoblastic Leukemia. (2004) (18)
The Genetics and Mechanisms of T-Cell Acute Lymphoblastic Leukemia. (2019) (17)
Cathepsin D in breast secretions from women with breast cancer. (1993) (17)
Malignant Lymphomas and Lymphadenopathies (2009) (17)
FYN–TRAF3IP2 induces NF-κB signaling-driven peripheral T-cell lymphoma (2021) (16)
MAPK-ERK is a central pathway in T-cell acute lymphoblastic leukemia that drives steroid resistance (2021) (16)
Tumor Suppressor HIPK2 Regulates Malignant Growth via Phosphorylation of Notch1. (2016) (15)
Subclonal NT5C2 mutations are associated with poor outcomes after relapse of pediatric acute lymphoblastic leukemia. (2020) (13)
TLX1-Induced T-cell Acute Lymphoblastic Leukemia (2011) (13)
Therapeutic Targeting of NOTCH 1 Signaling in T-Cell Acute Lymphoblastic Leukemia (2009) (12)
The HOX11/TLX1 Transcription Factor Oncogene Induces Chromosomal Aneuploidy in T-ALL. (2009) (12)
Absence of Biallelic TCR (cid:1) Deletion Predicts Early Treatment Failure in Pediatric T-Cell Acute Lymphoblastic Leukemia (2010) (12)
Oncogenic NOTCH 1 Control of MYC and PI 3 K : Challenges and Opportunities forAnti-NOTCH 1 Therapy inT-Cell Acute Lymphoblastic Leukemias and Lymphomas (2008) (12)
Small Molecule that Reverses Dexamethasone Resistance in T-cell Acute Lymphoblastic Leukemia (T-ALL). (2014) (12)
A Case of T‐cell Acute Lymphoblastic Leukemia Relapsed As Myeloid Acute Leukemia (2016) (11)
Supplementary Notes MicroRNA Expression Profiles Classify Human Cancers (2005) (11)
SOX11 is a mantle cell lymphoma oncogene. (2013) (11)
WT 1 mutations in TALL (2009) (10)
Common and rare variant associations with clonal haematopoiesis phenotypes (2022) (10)
Inhibition of mitochondrial complex I reverses NOTCH1-driven metabolic reprogramming in T-cell acute lymphoblastic leukemia (2022) (9)
Redundancy and Specificity of the Metalloprotease System Mediating Oncogenic NOTCH1 Activation in T-ALL. (2009) (9)
The SCF FBW 7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia (2007) (9)
PRC2 Inhibitors Overcome Glucocorticoid Resistance Driven by NSD2 Mutation in Pediatric Acute Lymphoblastic Leukemia. (2021) (8)
Glucocorticoid Resistance in Acute Lymphoblastic Leukemia: BIM Finally. (2018) (8)
Targeting S100A9–ALDH1A1–Retinoic Acid Signaling to Suppress Brain Relapse in EGFR-Mutant Lung Cancer (2022) (8)
Combinatorial ETS1-dependent control of oncogenic NOTCH1 enhancers in T-cell leukemia. (2020) (8)
Expression-Based Screen Identifies the Calcium Channel Antagonist Bepridil as a Notch1 Modulator in T-ALL. (2009) (7)
Genomic tools for dissecting oncogenic transcriptional networks in human leukemia (2009) (7)
Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies (2022) (7)
ChIP-on-chip significance analysis reveals ubiquitous transcription factor binding (2007) (7)
Tcf1 is essential for initiation of oncogenic Notch1-driven chromatin topology in T-ALL (2022) (6)
Detection of Marker-Free Precision Genome Editing and Genetic Variation through the Capture of Genomic Signatures (2020) (6)
Targeted cellular immunotherapy for T cell malignancies (2017) (6)
Gene expression profiling: will it complement or replace immunophenotyping? (2003) (6)
Aberrant cytokine production by nonmalignant cells in the pathogenesis of myeloproliferative tumors and response to JAK inhibitor therapies. (2015) (6)
Oncogenic AKT Signaling Negatively Regulates Glucocorticoid Receptor Function to Promote Glucocorticoid Resistance In T Cell Acute Lymphoblastic Leukemia (2010) (6)
Oncogenic Vav1-Myo1f induces therapeutically targetable macrophage-rich tumor microenvironment in peripheral T cell lymphoma (2022) (5)
Mitochondrial Complex I Inhibitor Iacs-010759 Reverses the NOTCH1-Driven Metabolic Reprogramming in T-ALL Via Blockade of Oxidative Phosphorylation: Synergy with Chemotherapy and Glutaminase Inhibition (2018) (5)
Therapeutic targeting of HES 1 transcriptional programs in TALL (2015) (5)
An oncogenic enhancer enemy (N-Me) in T-ALL (2015) (5)
83JAK-STAT inhibition mediates romidepsin and mechlorethamine synergism in Cutaneous T-cell Lymphoma. (2021) (4)
Fusion of NUP214 to ABL1 on amplified extrachromosomal elements in T-ALL. (2004) (4)
A Novel Class of Activating Mutations in NOTCH1 in T-ALL. (2007) (4)
Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma (2021) (4)
High-Throughput Mutational Profiling In AML: Mutational Analysis of the ECOG E1900 Trial (2010) (4)
Targeting NOTCH1 in T-ALL: Starving the dragon (2016) (4)
Intracellular cholesterol pools regulate oncogenic signaling and epigenetic circuitries in Early T-cell Precursor Acute Lymphoblastic Leukemia. (2021) (4)
Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models (2019) (3)
Mitochondrial Complex I Inhibition with Iacs-010759 in T-ALL Preclinical Models (2016) (3)
Role and Mechanisms of Rhoa G17V in the Pathogenesis of AITL (2016) (3)
Deregulation of enhancer structure, function, and dynamics in acute lymphoblastic leukemia. (2021) (3)
Patient Derived Xenograft (PDX) Models Recapitulate the Genomic-Driver Composition of Acute Leukemia Samples (2014) (3)
Inhibition of NOTCH1 Signaling and Glucocorticoid Therapy in T-ALL (2008) (3)
DNA Hydroxymethylation P rofiling Reveals that WT 1 Mutations Result in Loss of TET 2 Function in Acute Myeloid Leukemia (2014) (3)
Inhibition of NOTCH1 Signaling Reverses Glucocorticoid Resistance in T-ALL. (2007) (3)
ParMap, an Algorithm for the Identification of Complex Genomic Variations in Nextgen Sequencing Data (2010) (2)
MEF2C as Novel Oncogene for Early T-Cell Precursor (ETP) Leukemia (2010) (2)
Comment on Vegliante et al , page 2175 SOX 11 is a mantle cell lymphoma oncogene (2013) (2)
T-Cell Malignancies in Children and Adolescents: State of the Clinical and Biological Science (2013) (2)
Abstract A06: The chemokine receptor CXCR4 is essential for the maintenance of T cell acute lymphoblastic leukemia. (2015) (2)
ETV6-NCOA2 fusion induces T/Myeloid mixed-phenotype leukemia by transformation of non-thymic hematopoietic progenitors. (2021) (2)
Activating FLT 3 Mutations in CD 117 / KIT Positive T-Cell Acute Lymphoblastic Leukemias (2004) (2)
Activating Notch1 Mutations Are an Early Event in T-Cell Malignancy of Ikaros Point Mutant Mice. (2005) (2)
Modeling NOTCH1 driven T-cell Acute Lymphoblastic Leukemia in Mice. (2020) (2)
Preclinical Development Preclinical Analysis of the g-Secretase Inhibitor PF-03084014 in Combination with Glucocorticoids in T-cell Acute Lymphoblastic Leukemia (2012) (2)
Computational structure prediction methods enable the systematic identification of oncogenic mutations (2022) (2)
Role of Rhoa G17V in Cell Migration and Transformation in Angioimmunoblastic T-Cell Lymphoma (2018) (2)
ETV6 Is An Early T-Cell Progenitor (ETP) Specific Tumor Suppressor Gene in Adult T-ALL (2011) (2)
Genome-wide RNAi screen identifies miR-19 targets in Notch-induced acute T-cell leukaemia ( TALL ) (2010) (2)
16. Molecular pathogenesis of malignant lymphomas: PTCL, NOS and AITL (2016) (1)
Notch Signaling Is Required for Mast Cell Development In the Zebrafish and May Represent a Novel Therapeutic Strategy In Systemic Mastocytosis (2010) (1)
Epigenetic reversal of hematopoietic stem cell aging in Phf6-knockout mice (2022) (1)
Abstract B134: IMPDH1 and IMPDH2 as therapeutic targets in acute lymphoblastic leukemia (2019) (1)
Genome-Wide Transcriptional Regulatory Networks Downstream of TAL1/SCL in T-Cell Acute Lymphoblastic Leukemia. (2004) (1)
Notch Signaling Is Required for Mast Cell Development in the Zebrafish. (2009) (1)
VAV1 Activating Mutations and Translocations in Peripheral T-Cell Lymphomas (2016) (1)
randomized prospective trial (UKALL XII/ECOG 2993) immunophenotype, cytogenetics, and outcome from the large T-cell acute lymphoblastic leukemia in adults: clinical features, (2013) (1)
ParMap, an algorithm for the identification of small genomic insertions and deletions in nextgen sequencing data (2010) (1)
acute lymphoblastic leukemia Transcriptional regulatory networks downstream of TAL1/SCL in t-cell (2013) (1)
TLX 1 induced T-cell acute lymphoblastic leukemia (2011) (1)
Oncogenic Transcriptional Programs Controlled by TLX1/HOX11 and TLX3/HOX11L2 in T-ALL (2009) (1)
Identification of TAL1/SCL Target Genes through siRNA and Microarray Expression Analysis. (2004) (1)
NOTCH1: a therapeutic target for T cell acute lymphoblastic leukemia/lymphoma (2009) (1)
Abstract 965: An oncogenic metabolic switch mediates resistance to NOTCH1 inhibition in T-ALL (2014) (1)
An Oncogenic Metabolic Switch Mediates Resistance to NOTCH1 Inhibition in T-ALL (2012) (1)
Therapeutic Utility of PI3Kγ Inhibition in Leukemogenesis and Tumor Cell Survival (2012) (1)
Functional mapping of PHF6 complexes in chromatin remodeling, replication dynamics and DNA repair. (2022) (1)
De Novo Purine Biosynthesis in Drug Resistance and Tumor Relapse of Childhood ALL (2015) (1)
Using the Zebrafish As a Tool for Modeling Systemic Mastocytosis (2011) (1)
Reversal of glucocorticoid resistance by the g-secretase inhibitor PF-03084014 in T-cell acute lymphoblastic leukemia. (2011) (1)
Mutational Loss of PTEN Induces Resistance to NOTCH1 Inhibition in T-ALL. (2007) (1)
Glutaminase Inhibition Overcomes Acquired Resistance to Mitochondrial Complex I in NOTCH1-Driven T-Cell Acute Lymphoblastic Leukemias (T-ALL) Via Block of Glutamine Driven Reductive Metabolism (2019) (1)
The Central Role of MAPK-ERK Signaling in IL7-Dependent and IL7-Independent Steroid Resistance Reveals a Broad Application of MEK-Inhibitors Compared to JAK1/2-Inhibition in T-ALL (2020) (1)
Overcoming NOTCH1-Driven Chemoresistance in T-Cell Acute Lymphoblastic Leukemia Via Metabolic Intervention with Oxphos Inhibitor (2020) (1)
ALL-144: Oncogenic Deregulation of BCL11B in Lineage Ambiguous Leukemia (2021) (0)
H3K27me3 erasers, novel targets in T-cell acute lymphoblastic leukaemia (2013) (0)
Crystal structure of the double mutant (D52N/R367Q) of NT5C2-537X in the active state, Northeast Structural Genomics Target (2018) (0)
Identification of NOTCH1-Controlled Transcriptional Programs In Human T-Cell Development (2010) (0)
Abstract PO-41: Expression of Vav1-Myo1F fusion affects T-cell differentiation and induces T-cell lymphoma (2020) (0)
Abstract A35: Discovery of driver-type therapeutic targets to reverse glucocorticoid resistance in T-ALL (2012) (0)
Abstract PR03: Delineating the roles of lysine 27 methylation-associated epigenetic modulators in T cell leukemia. (2015) (0)
CHAPTER 23 – Chromosomal Translocations in B-Cell Leukemias and Lymphomas (2004) (0)
Targeting the Mitochondria Metabolism of T‐ALL with Novel Mitochondrial Complex I Inhibitor IACS‐010759: Abstract: ALL‐033 (2017) (0)
Erratum: Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia (Nature Immunology (2010) 11 (717-724)) (2010) (0)
Genetic Mechanisms in T-Cell Acute Lymphoblastic Leukemia (2022) (0)
Abstract 1128: Identification of arginine methyltransferase PRMT5 as a novel therapeutic target in T-cell acute lymphoblastic leukemia (2017) (0)
Abstract 49: Synergistic antileukemic therapies in NOTCH1-induced T-ALL (2017) (0)
Microarray Analyses in a Case-Control Cohort of T-ALL Samples Identifies Gene Signature of Potential Prognostic Significance. (2005) (0)
Crystal structure of the double mutant (D52N/L375F) of NT5C2-537X in the active state, Northeast Structural Genomics Target (2018) (0)
TAL Family of bHLH Genes (2013) (0)
Cloning and Expression Analysis of Human Bleomycin Hydrolase , a Cysteine Proteinase Involved in Chemotherapy Resistance 1 (2006) (0)
Abstract 4595: Activating mutations in theNT5C2nucleotidase gene drive chemotherapy resistance in relapsed ALL. (2013) (0)
Genomic technologies in leukemia and lymphoma: a review series (2009) (0)
Multivalent Small-Molecule Pan-RAS Inhibitors Graphical (2017) (0)
BCL11B Mutations In T-Cell Acute Lymphoblastic Leukemia (2010) (0)
S130 TRANSIENT SUBCLONES CARRYING NT5C2 MUTATIONS DEFINE A HIGH-RISK PATIENT GROUP WITH POOR OUTCOME IN PEDIATRIC RELAPSED B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (2019) (0)
Mutational Landscape, Clonal Evolution Patterns and Role of RAS Mutations in Relapsed Acute Lymphoblastic Leukemia (2016) (0)
The H3K27me3 demethylase UTX is a tumor suppressor in T-cell acute lymphoblastic leukaemia (2013) (0)
Abstract IA05: Oncogenic signaling pathways and resistance to therapy in T-ALL (2016) (0)
discovery in T-ALL An IL-7-dependent human leukemia T-cell line as a valuable tool for drug (2013) (0)
Abstract 1: Novel pediatric AML patient risk stratification by inferred protein activity through integrative network analysis and machine learning (2021) (0)
AWARD NUMBER: W81XWH-10-1-0596 TITLE: Targeting Class I PI3Ks in the Treatment of T-cell Acute Lymphoblastic Leukemia (2013) (0)
Molecular targets of Notch signaling, HES1 and c-Myc, oppose a PTEN-dependent check on survival, differentiation and proliferation of TCR-beta-selected thymocytes (111.21) (2012) (0)
Abstract C005: NT5C2 small molecule inhibitor for the reversal of 6-MP resistance in acute lymphoblastic leukemia (2019) (0)
Targeting Class I PI3Ks in the Treatment of T-cell Acute Lymphoblastic Leukemia (2013) (0)
Assessment of therapeutic effects of Notch-1 blockade in T-acute lymphoblastic leukemia xenograft models (2012) (0)
CSL–MAML-dependent Notch1 signaling controls T lineage–specific IL-7Rα gene expression in early human thymopoiesis and leukemia (2009) (0)
Molecular Pathways TLX 1-Induced T-cell Acute Lymphoblastic Leukemia (2011) (0)
O023 Oncogenic IL-7R gain-of-function mutations in childhood T-ALL (2011) (0)
H3K27me3 erasers are novel targets in T-cell lymphoblastic leukaemia (2013) (0)
Abstract IA22: An oncogenic enhancer drives NOTCH1-induced leukemia. (2015) (0)
Abstract PR02: Mechanisms of NT5C2 activating mutations driving thiopurine resistance in relapsed lymphoblastic leukemia (2017) (0)
Leukemias and Lymphomas: Genetics (2006) (0)
Identification of a Novel T-ALL Entity with NKX2-1/NKX2-2 Rearrangements (2010) (0)
A New Recurrent 9q34 Duplication in Pediatric T-Cell Acute Lymphoblastic Leukemia. (2005) (0)
Crystal structure of the single mutant (D52N) of NT5C2-537X in the basal state, Northeast Structural Genomics Consortium Target (2018) (0)
Crystal structure of the double mutant (D52N/R367Q) of the full-length NT5C2 in the basal state (2018) (0)
O22: A new recurrent 9q34 duplication in pediatric T-cell acute lymphoblastic leukemia (2005) (0)
74 : IL-7R: Mutations in T-ALL and polymorphisms in autoimmunity (2013) (0)
Abstract B24: Delineating the roles of lysine 27 methylation-associated epigenetic modulators in T cell leukemia. (2015) (0)
An Oncogene-Regulated Epigenetic Switch in T Cell Acute Lymphoblastic Leukemia (2014) (0)
Phosphoproteomic profiling of T cell acute lymphoblastic leukemia reveals targetable kinases and combination treatment strategies (2022) (0)
192 Gene expression profiling of mechlorethamine and romidepsin combination shows downregulation of the JAK/STAT pathway in cutaneous T-cell lymphoma (2018) (0)
Abstract A07: Characterizing the specific oncogenic and tumor suppressor roles of H3K27me3 epigenetic modulators in T cell leukemia (2013) (0)
A selective BCL-XL PROTAC degrader achieves safe and potent antitumor activity (2019) (0)
Role of Vav1 Genomic Alterations in T-Cell Differentiation and Transformation in Peripheral T-Cell Lymphoma (2019) (0)
Abstract A226: Identification of new synergistic compounds for the treatment of NOTCH-driven T-ALL. (2013) (0)
Synergistic Targeting of Protein Translation and Inhibition of NOTCH Signaling in T-ALL (2015) (0)
Mechanisms of NT5C2 mutations Driving Thiopurine Resistance in Acute Lymphoblastic Leukemia (2017) (0)
Metabolomic profiling of primary leukemia samples (2021) (0)
Unlike Paediatric T-ALL, Notch-1 and FBXW7 Mutations Do Not Seem to Predict a Better Outcome in Adult Patients: Data from the UKALLXII/ECOG2993 Protocol (2008) (0)
Non-Canonical Exon Usage in Pediatric Leukemia: Implications for Chemoresistance (2022) (0)
Crystal structure of the single mutant (D52N) of NT5C2-Q523X in the basal state (2018) (0)
Mechanisms of Therapeutic Response to Tipifarnib in a Mouse Model of Angioimmunoblastic T-Cell Lymphoma (2020) (0)
Pharmacological inhibition of NT5C2 reverses genetic and non-genetic drivers of 6-MP resistance in acute lymphoblastic leukemia. (2022) (0)
Abstract 3928: Therapeutic targeting of NOTCH1 and neddylation pathway in T cell acute lymphoblastic leukemia (2023) (0)
Suppression of GATA3 Binding Drives Selective Abrogation of NOTCH1-MYC Enhancer Activity By Nucleosome Invasion in Thymocyte Development and Leukemia (2018) (0)
Precursor T-Cell Neoplasms (2010) (0)
3018 – BIOENGINEERED HUMAN MICROTISSUE MODEL OF HEALTHY AND LEUKEMIC BONE MARROW (2022) (0)
Crystal structure of the double mutant (D52N/D407A) of NT5C2-537X in the active state (2018) (0)
Challenges and Opportunities for Effective NOTCH1 Targeting in T-ALL. (2008) (0)
LYMPHOID NEOPLASIA Genetic loss of SH2B3 in acute lymphoblastic leukemia (2013) (0)
Chemical Genomic Screen Identifies Ionophores as Modulators of Notch1 in T-ALL (2008) (0)
Crystal structure of the single mutant (D52N) of the full-length NT5C2 in the basal state (2018) (0)
293 Rational design of combination therapy in cutaneous T-cell lymphoma using an HDAC inhibitor and alkylating agent (2017) (0)
Oncogenic hijacking of the stress response machinery in T cell acute lymphoblastic leukemia (2018) (0)
Clonal Evolution and Sub-Clonal Architecture In Paediatric T-Cell Acute Lymphoblastic Leukaemia (T-ALL) (2013) (0)
N-Me, a Long Range T-Cell Specific Oncogenic Enhancer in T-ALL (2014) (0)
Crystal structure of the double mutant (D52N/R367Q) of NT5C2-537X in the basal state, Northeast Structural Genomics Consortium Target (2018) (0)
Identification of Oncogenic Pathways of T-Acute Lymphoblastic Leukemia (T-ALL) through Gene Expression Profiling of Mouse Tumor Models. (2006) (0)
The Mutational Landscape of CTCL and Sezary Syndrome (2015) (0)
Familial and Acquired SH2B3 mutations in ALL (2012) (0)
Abstract 1875: Oxidative metabolism as a novel therapeutic target to eradicate T-ALL with mitochondrial complex I inhibitor IACS-010759 (2018) (0)
FBW7 E3-Ligase Mutations Are Associated with T Cell Leukemia. (2007) (0)
Current perspectives in T-ALL (2019) (0)
The Sub-Clonal Complexity of STIL-TAL1 T-ALL (2014) (0)
Inhibition of the myeloid master regulator PU.1 as a therapeutic strategy in acute myeloid leukemia (2017) (0)
Expression of Vav1-Myo1F Fusion Affects T-Cell Differentiation and Induces T-Cell Lymphoma (2020) (0)
Post-Translational Mechanisms of NT5C2 Activation As Non-Genetic Drivers of Chemotherapy Resistance in Relapsed Acute Lymphoblastic Leukemia (2019) (0)
667 Targeting the JAK/STAT pathway for CTCL therapy (2019) (0)
Childhood Leukemias: Molecular genetics of acute lymphoblastic leukemia (2006) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Adolfo A. Ferrando?

Adolfo A. Ferrando is affiliated with the following schools: